<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="758">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>23/09/2005</approvaldate>
  <actrnumber>ACTRN12605000495628</actrnumber>
  <trial_identification>
    <studytitle>The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-alpha gene  to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAART</studytitle>
    <scientifictitle>The Relationship of single nucleotide polymorphisms in the Interleukin-7 receptor-gene  to CD4+ immune recovery in HIV infected patients who begin antiretroviral treatment with HAART</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>The determinants of immune recovery following institution of Highly Active Antiretroviral Treatment in HIV infected patients</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>None. This is an observational study.</interventions>
    <comparator>There is no control group. This is an observational study.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluation of the determinants of immune recovery (namely CD4+ T lymphocyte and HIV viral load). These factors include age, sex, cigarette smoking, Hepatitis C co-infection, CD8+ T-lymphocyte count, nadir and baseline CD4+ T-lymphocyte, baseline HIV viral load, time to undetectable HIV viral load and composition of HAART.</outcome>
      <timepoint>There is no timepoint for this outcome.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Investigating whether interleukin-7 receptor (IL-7Ralpha) polymorphisms and IL-7Ralpha expression may be a determinant of immune recovery.</outcome>
      <timepoint>There is no timepoint for this outcome.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>There is no secondary outcome.</outcome>
      <timepoint>There is no timepoint for this outcome.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals. Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of 500 copies/mL on bDNA testing (versions 2 and 3) and &lt;400 copies/ml measured by RT-PCR assay by 6 months treatment. CD4 cell count &lt;500 at commencement of HAART. Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclude patients treated for HIV seroconversion illness. Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC</primarysponsorname>
    <primarysponsoraddress>GPO Box 1421 Canberra ACT 2601</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC program grant.</fundingname>
      <fundingaddress>GPO Box 1421 Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>New secondary sponsor name. Please modify.</sponsorname>
      <sponsoraddress>New secondary sponsor address. Please modify.</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress>Commercial Rd, Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Sharon Lewin</name>
      <address>Infectious Diseases Unit
Alfred Hospital
2nd Floor
Burnet Institute
Commercial Road
Mebourne VIC 3004</address>
      <phone>+61 3 92763009</phone>
      <fax>+61 3 92762431</fax>
      <email>S.Lewin@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Jennifer Hoy</name>
      <address>Infectious Diseases Unit
Alfred Hospital
2nd Floor
Burnet Institute
Commercial Road
Mebourne VIC 3004</address>
      <phone>+61 3 92766900</phone>
      <fax>+61 3 92762431</fax>
      <email>Jennifer.Hoy@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>